Showing results (461-470 of 730) with videos related to
Sort By:
Pageof 73
Journal of the American Heart Association|August 5, 2022
Repeated Measures of Modified Rankin Scale Scores to Assess Functional Recovery From Stroke: AFFINITY Study FindingsAlexander Chye, Maree L Hackett, Graeme J Hankey, et al.Stroke|October 25, 2012
B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudyMargherita Cavalieri, Reinhold Schmidt, Christopher Chen, et al.JAMA Network Open|December 9, 2022
Association of Psychosocial Stress With Risk of Acute StrokeCatriona Reddin, Robert Murphy, Graeme J Hankey, et al.Lancet (London, England)|May 29, 2012
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial, Peter Sandercock, Joanna M Wardlaw, et al.Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.BMC Medical Research Methodology|October 18, 2021
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trialsLisa J Woodhouse, Alan A Montgomery, Jonathan Mant, et al.International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.Journal of Hypertension|June 1, 2026
Update from the National Hypertension Taskforce of Australia: prevalence, treatment and control rates of hypertension between 2022 and 2024 - implications and future directionsAmelie H Ohlrogge, Xiaoyue Xu, Andrew Goodman, et al.Journal of Human Hypertension|March 11, 2020
Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysisChau L B Ho, Sharon Sanders, Monique Breslin, et al.Pageof 73